CureGene Doses First Patient in Pivotal US Trial of Evategrel
CureGene achieves first participant dosed in US pivotal trial for Evategrel (CG-0255), a best-in-class antiplatelet drug, accelerating global commercialisation.
CureGene Pharmaceutical | 23/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy